Media

Watch a seminar by Immunovative's founder, CEO and inventor of Mirror Effect technology presented to an private audience by invitation only at the Montreal University Club. In this seminar, Dr. Har-Noy describes the current status of the war against cancer and how immunotherapy in general and AlloStim in  particular can make a difference in the life's of cancer patients.  This seminar was conducted in 2012 before the wave of new immunotherapy drugs were approved by the US FDA.   

A New Strategy for Immunotherapy of Cancer, Oncology News, September / October 2009

Cancer immunotherapy holds out great promise, but good animal results have not been successfully translated to the clinic. This re-evaluation brings forward new ideas are about immune responses in cancer patients that may improve strategies in future.

SPECIALITY INFORMATION

patients


Treatment strategy designed to use the power of the human immune system to kill tumors and prevent their recurrence.
No requirement for a matched donor or chemotherapy/radiation conditioning prior to treatment.
Innovative technology – proven and non-toxic.
read more

Healthcare professionals


Therapeutic anti-tumor vaccine developed from core break-through technology called the "Mirror Effect™“ which opens a pathway to treating patients with metastatic cancer that have failed all available therapy options.
Elicits a GVT-like mechanism without the GVHD toxicity.
read more

Investors


Privately-held Israeli biopharmaceutical company spin out from Hadassah-Hebrew University Medical Center with headquarters in Jerusalem.

Over 200 individual private shareholders and grant support from the Israel Office of the Chief Scientist.
read more